Rivaroxaban (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rivaroxaban" in Italian language version.

refsWebsite

Global rank Italian rank

4^th place

9^th place

2^nd place

7^th place

799^th place

22^nd place

6^th place

8^th place

2web.archive.org

1^st place

1^st place

2agenziafarmaco.gov.it

low place

1,603^rd place

68^th place

57^th place

agenziafarmaco.gov.it

farmaci.agenziafarmaco.gov.it

farmaci.agenziafarmaco.gov.it, https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000708_038744_RCP.pdf&retry=0&sys=m0b1l3 Titolo mancante per url url (aiuto).

agenziafarmaco.gov.it

AIFA, Comunicazione relativa ai nuovi anticoagulanti orali Eliquis®, Pradaxa®, Xarelto® Importante informativa sui fattori di rischio di sanguinamento – (PDF), su agenziafarmaco.gov.it, Agenzia Italiana del farmaco, 11 settembre 2013. URL consultato il 30 settembre 2013.

archive.org

D. Kubitza, M. Becka; B. Voith; M. Zuehlsdorf; G. Wensing, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor., in Clin Pharmacol Ther, vol. 78, n. 4, Oct 2005, pp. 412-21, DOI:10.1016/j.clpt.2005.06.011, PMID 16198660.
E. Perzborn, S. Roehrig; A. Straub; D. Kubitza; W. Mueck; V. Laux, Rivaroxaban: a new oral factor Xa inhibitor., in Arterioscler Thromb Vasc Biol, vol. 30, n. 3, Mar 2010, pp. 376-81, DOI:10.1161/ATVBAHA.110.202978, PMID 20139357.
MM. Samama, The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants., in Thromb Res, vol. 127, n. 6, Jun 2011, pp. 497-504, DOI:10.1016/j.thromres.2010.09.008, PMID 20888031.
S. Turun, L. Banghua; Y. Yuan; L. Zhenhui; N. Ying; C. Jin, A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement., in Thromb Res, vol. 127, n. 6, Jun 2011, pp. 525-34, DOI:10.1016/j.thromres.2011.01.016, PMID 21397931.

doi.org

dx.doi.org

E. Perzborn, J. Strassburger; A. Wilmen; J. Pohlmann; S. Roehrig; KH. Schlemmer; A. Straub, In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor., in J Thromb Haemost, vol. 3, n. 3, Mar 2005, pp. 514-21, DOI:10.1111/j.1538-7836.2005.01166.x, PMID 15748242.
D. Kubitza, M. Becka; B. Voith; M. Zuehlsdorf; G. Wensing, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor., in Clin Pharmacol Ther, vol. 78, n. 4, Oct 2005, pp. 412-21, DOI:10.1016/j.clpt.2005.06.011, PMID 16198660.
AG. Turpie, WD. Fisher; KA. Bauer; LM. Kwong; MW. Irwin; P. Kälebo; F. Misselwitz; M. Gent, BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study., in J Thromb Haemost, vol. 3, n. 11, Nov 2005, pp. 2479-86, DOI:10.1111/j.1538-7836.2005.01602.x, PMID 16241946.
E. Perzborn, S. Roehrig; A. Straub; D. Kubitza; W. Mueck; V. Laux, Rivaroxaban: a new oral factor Xa inhibitor., in Arterioscler Thromb Vasc Biol, vol. 30, n. 3, Mar 2010, pp. 376-81, DOI:10.1161/ATVBAHA.110.202978, PMID 20139357.
MP. Gulseth, J. Michaud; EA. Nutescu, Rivaroxaban: an oral direct inhibitor of factor Xa., in Am J Health Syst Pharm, vol. 65, n. 16, Aug 2008, pp. 1520-9, DOI:10.2146/ajhp070624, PMID 18693206.
MM. Samama, The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants., in Thromb Res, vol. 127, n. 6, Jun 2011, pp. 497-504, DOI:10.1016/j.thromres.2010.09.008, PMID 20888031.
R. Kreutz, Pharmacodynamic and pharmacokinetic basics of rivaroxaban., in Fundam Clin Pharmacol, vol. 26, n. 1, Feb 2012, pp. 27-32, DOI:10.1111/j.1472-8206.2011.00981.x, PMID 21848931.
P. Kakar, T. Watson; GY. Lip, Rivaroxaban., in Drugs Today (Barc), vol. 43, n. 3, Mar 2007, pp. 129-36, DOI:10.1358/dot.2007.43.3.1067345, PMID 17380210.
ST. Duggan, LJ. Scott; GL. Plosker, Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery., in Drugs, vol. 69, n. 13, 2009, pp. 1829-51, DOI:10.2165/11200890-000000000-00000, PMID 19719335.
M. Stevenson, A. Scope; M. Holmes; A. Rees; E. Kaltenthaler, Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal., in Health Technol Assess, 13 Suppl 3, Oct 2009, pp. 43-8, DOI:10.3310/hta13suppl3/07, PMID 19846028.
ST. Duggan, Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery., in Am J Cardiovasc Drugs, vol. 12, n. 1, Feb 2012, pp. 57-72, DOI:10.2165/11208470-000000000-00000, PMID 22272729.
YK. Loke, CS. Kwok, Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison., in J Clin Pharm Ther, vol. 36, n. 1, Feb 2011, pp. 111-24, DOI:10.1111/j.1365-2710.2010.01162.x, PMID 21198726.
T. Goff, G. Kontakis; PV. Giannoudis, Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update., in Expert Opin Drug Saf, vol. 10, n. 5, Sep 2011, pp. 687-96, DOI:10.1517/14740338.2011.558500, PMID 21406027.
LM. Kwong, Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data., in Vasc Health Risk Manag, vol. 7, 2011, pp. 461-6, DOI:10.2147/VHRM.S4441, PMID 21822393.
JP. Piccini, RD. Lopes; KW. Mahaffey, Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation., in Curr Opin Cardiol, vol. 25, n. 4, Jul 2010, pp. 312-20, DOI:10.1097/HCO.0b013e32833a524f, PMID 20520539.
LR. Bereznicki, GM. Peterson, New antithrombotics for atrial fibrillation., in Cardiovasc Ther, vol. 28, n. 5, Oct 2010, pp. 278-86, DOI:10.1111/j.1755-5922.2010.00209.x, PMID 20645985.
M. Baumhäkel, SH. Schirmer; M. Böhm, [Novel anticoagulants for stroke prevention in atrial fibrillation]., in Dtsch Med Wochenschr, vol. 135, n. 46, Nov 2010, pp. 2304-8, DOI:10.1055/s-0030-1267516, PMID 21064013.
P. Prandoni, Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study., in Eur J Haematol, vol. 89, n. 4, Oct 2012, pp. 281-7, DOI:10.1111/ejh.12002, PMID 22834998.
AT. Cohen, M. Dobromirski, The use of rivaroxaban for short- and long-term treatment of venous thromboembolism., in Thromb Haemost, vol. 107, n. 6, Jun 2012, pp. 1035-43, DOI:10.1160/TH11-12-0859, PMID 22371186.
B. Brenner, R. Hoffman, Emerging options in the treatment of deep vein thrombosis and pulmonary embolism., in Blood Rev, vol. 25, n. 5, Sep 2011, pp. 215-21, DOI:10.1016/j.blre.2011.04.003, PMID 21605928.
V. Laux, E. Perzborn; S. Heitmeier; G. von Degenfeld; E. Dittrich-Wengenroth; A. Buchmüller; C. Gerdes; F. Misselwitz, Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?, in Thromb Haemost, vol. 102, n. 5, Nov 2009, pp. 892-9, DOI:10.1160/TH09-02-0134, PMID 19888525.
S. Turun, L. Banghua; Y. Yuan; L. Zhenhui; N. Ying; C. Jin, A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement., in Thromb Res, vol. 127, n. 6, Jun 2011, pp. 525-34, DOI:10.1016/j.thromres.2011.01.016, PMID 21397931.
P. Mismetti, S. Laporte, [Rivaroxaban: clinical pharmacology]., in Ann Fr Anesth Reanim, 27 Suppl 3, Dec 2008, pp. S16-21, DOI:10.1016/S0750-7658(08)75142-6, PMID 19185782.

europa.eu

ema.europa.eu

European Medicines Agency, Xarelto:rivaroxaban summary of opinion, su ema.europa.eu, 22 settembre 2011. URL consultato il 25 novembre 2012.

nih.gov

ncbi.nlm.nih.gov

E. Perzborn, J. Strassburger; A. Wilmen; J. Pohlmann; S. Roehrig; KH. Schlemmer; A. Straub, In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor., in J Thromb Haemost, vol. 3, n. 3, Mar 2005, pp. 514-21, DOI:10.1111/j.1538-7836.2005.01166.x, PMID 15748242.
D. Kubitza, M. Becka; B. Voith; M. Zuehlsdorf; G. Wensing, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor., in Clin Pharmacol Ther, vol. 78, n. 4, Oct 2005, pp. 412-21, DOI:10.1016/j.clpt.2005.06.011, PMID 16198660.
AG. Turpie, WD. Fisher; KA. Bauer; LM. Kwong; MW. Irwin; P. Kälebo; F. Misselwitz; M. Gent, BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study., in J Thromb Haemost, vol. 3, n. 11, Nov 2005, pp. 2479-86, DOI:10.1111/j.1538-7836.2005.01602.x, PMID 16241946.
E. Perzborn, S. Roehrig; A. Straub; D. Kubitza; W. Mueck; V. Laux, Rivaroxaban: a new oral factor Xa inhibitor., in Arterioscler Thromb Vasc Biol, vol. 30, n. 3, Mar 2010, pp. 376-81, DOI:10.1161/ATVBAHA.110.202978, PMID 20139357.
MP. Gulseth, J. Michaud; EA. Nutescu, Rivaroxaban: an oral direct inhibitor of factor Xa., in Am J Health Syst Pharm, vol. 65, n. 16, Aug 2008, pp. 1520-9, DOI:10.2146/ajhp070624, PMID 18693206.
MM. Samama, The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants., in Thromb Res, vol. 127, n. 6, Jun 2011, pp. 497-504, DOI:10.1016/j.thromres.2010.09.008, PMID 20888031.
R. Kreutz, Pharmacodynamic and pharmacokinetic basics of rivaroxaban., in Fundam Clin Pharmacol, vol. 26, n. 1, Feb 2012, pp. 27-32, DOI:10.1111/j.1472-8206.2011.00981.x, PMID 21848931.
P. Kakar, T. Watson; GY. Lip, Rivaroxaban., in Drugs Today (Barc), vol. 43, n. 3, Mar 2007, pp. 129-36, DOI:10.1358/dot.2007.43.3.1067345, PMID 17380210.
JD. Douketis, Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management., in Curr Pharm Des, vol. 16, n. 31, 2010, pp. 3436-41, PMID 20858185.
ST. Duggan, LJ. Scott; GL. Plosker, Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery., in Drugs, vol. 69, n. 13, 2009, pp. 1829-51, DOI:10.2165/11200890-000000000-00000, PMID 19719335.
M. Stevenson, A. Scope; M. Holmes; A. Rees; E. Kaltenthaler, Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal., in Health Technol Assess, 13 Suppl 3, Oct 2009, pp. 43-8, DOI:10.3310/hta13suppl3/07, PMID 19846028.
ST. Duggan, Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery., in Am J Cardiovasc Drugs, vol. 12, n. 1, Feb 2012, pp. 57-72, DOI:10.2165/11208470-000000000-00000, PMID 22272729.
YK. Loke, CS. Kwok, Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison., in J Clin Pharm Ther, vol. 36, n. 1, Feb 2011, pp. 111-24, DOI:10.1111/j.1365-2710.2010.01162.x, PMID 21198726.
T. Goff, G. Kontakis; PV. Giannoudis, Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update., in Expert Opin Drug Saf, vol. 10, n. 5, Sep 2011, pp. 687-96, DOI:10.1517/14740338.2011.558500, PMID 21406027.
LM. Kwong, Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data., in Vasc Health Risk Manag, vol. 7, 2011, pp. 461-6, DOI:10.2147/VHRM.S4441, PMID 21822393.
JP. Piccini, RD. Lopes; KW. Mahaffey, Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation., in Curr Opin Cardiol, vol. 25, n. 4, Jul 2010, pp. 312-20, DOI:10.1097/HCO.0b013e32833a524f, PMID 20520539.
LR. Bereznicki, GM. Peterson, New antithrombotics for atrial fibrillation., in Cardiovasc Ther, vol. 28, n. 5, Oct 2010, pp. 278-86, DOI:10.1111/j.1755-5922.2010.00209.x, PMID 20645985.
M. Baumhäkel, SH. Schirmer; M. Böhm, [Novel anticoagulants for stroke prevention in atrial fibrillation]., in Dtsch Med Wochenschr, vol. 135, n. 46, Nov 2010, pp. 2304-8, DOI:10.1055/s-0030-1267516, PMID 21064013.
L. Kosar, M. Jin; R. Kamrul; B. Schuster, Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed., in Can Fam Physician, vol. 58, n. 8, Aug 2012, pp. 850-8, PMID 22893338.
P. Prandoni, Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study., in Eur J Haematol, vol. 89, n. 4, Oct 2012, pp. 281-7, DOI:10.1111/ejh.12002, PMID 22834998.
AT. Cohen, M. Dobromirski, The use of rivaroxaban for short- and long-term treatment of venous thromboembolism., in Thromb Haemost, vol. 107, n. 6, Jun 2012, pp. 1035-43, DOI:10.1160/TH11-12-0859, PMID 22371186.
B. Brenner, R. Hoffman, Emerging options in the treatment of deep vein thrombosis and pulmonary embolism., in Blood Rev, vol. 25, n. 5, Sep 2011, pp. 215-21, DOI:10.1016/j.blre.2011.04.003, PMID 21605928.
V. Laux, E. Perzborn; S. Heitmeier; G. von Degenfeld; E. Dittrich-Wengenroth; A. Buchmüller; C. Gerdes; F. Misselwitz, Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?, in Thromb Haemost, vol. 102, n. 5, Nov 2009, pp. 892-9, DOI:10.1160/TH09-02-0134, PMID 19888525.
S. Turun, L. Banghua; Y. Yuan; L. Zhenhui; N. Ying; C. Jin, A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement., in Thromb Res, vol. 127, n. 6, Jun 2011, pp. 525-34, DOI:10.1016/j.thromres.2011.01.016, PMID 21397931.
P. Mismetti, S. Laporte, [Rivaroxaban: clinical pharmacology]., in Ann Fr Anesth Reanim, 27 Suppl 3, Dec 2008, pp. S16-21, DOI:10.1016/S0750-7658(08)75142-6, PMID 19185782.

oadoi.org

E. Perzborn, J. Strassburger; A. Wilmen; J. Pohlmann; S. Roehrig; KH. Schlemmer; A. Straub, In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor., in J Thromb Haemost, vol. 3, n. 3, Mar 2005, pp. 514-21, DOI:10.1111/j.1538-7836.2005.01166.x, PMID 15748242.
AG. Turpie, WD. Fisher; KA. Bauer; LM. Kwong; MW. Irwin; P. Kälebo; F. Misselwitz; M. Gent, BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study., in J Thromb Haemost, vol. 3, n. 11, Nov 2005, pp. 2479-86, DOI:10.1111/j.1538-7836.2005.01602.x, PMID 16241946.
MP. Gulseth, J. Michaud; EA. Nutescu, Rivaroxaban: an oral direct inhibitor of factor Xa., in Am J Health Syst Pharm, vol. 65, n. 16, Aug 2008, pp. 1520-9, DOI:10.2146/ajhp070624, PMID 18693206.
R. Kreutz, Pharmacodynamic and pharmacokinetic basics of rivaroxaban., in Fundam Clin Pharmacol, vol. 26, n. 1, Feb 2012, pp. 27-32, DOI:10.1111/j.1472-8206.2011.00981.x, PMID 21848931.
P. Kakar, T. Watson; GY. Lip, Rivaroxaban., in Drugs Today (Barc), vol. 43, n. 3, Mar 2007, pp. 129-36, DOI:10.1358/dot.2007.43.3.1067345, PMID 17380210.
ST. Duggan, LJ. Scott; GL. Plosker, Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery., in Drugs, vol. 69, n. 13, 2009, pp. 1829-51, DOI:10.2165/11200890-000000000-00000, PMID 19719335.
M. Stevenson, A. Scope; M. Holmes; A. Rees; E. Kaltenthaler, Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal., in Health Technol Assess, 13 Suppl 3, Oct 2009, pp. 43-8, DOI:10.3310/hta13suppl3/07, PMID 19846028.
ST. Duggan, Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery., in Am J Cardiovasc Drugs, vol. 12, n. 1, Feb 2012, pp. 57-72, DOI:10.2165/11208470-000000000-00000, PMID 22272729.
YK. Loke, CS. Kwok, Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison., in J Clin Pharm Ther, vol. 36, n. 1, Feb 2011, pp. 111-24, DOI:10.1111/j.1365-2710.2010.01162.x, PMID 21198726.
T. Goff, G. Kontakis; PV. Giannoudis, Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update., in Expert Opin Drug Saf, vol. 10, n. 5, Sep 2011, pp. 687-96, DOI:10.1517/14740338.2011.558500, PMID 21406027.
LM. Kwong, Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data., in Vasc Health Risk Manag, vol. 7, 2011, pp. 461-6, DOI:10.2147/VHRM.S4441, PMID 21822393.
JP. Piccini, RD. Lopes; KW. Mahaffey, Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation., in Curr Opin Cardiol, vol. 25, n. 4, Jul 2010, pp. 312-20, DOI:10.1097/HCO.0b013e32833a524f, PMID 20520539.
LR. Bereznicki, GM. Peterson, New antithrombotics for atrial fibrillation., in Cardiovasc Ther, vol. 28, n. 5, Oct 2010, pp. 278-86, DOI:10.1111/j.1755-5922.2010.00209.x, PMID 20645985.
M. Baumhäkel, SH. Schirmer; M. Böhm, [Novel anticoagulants for stroke prevention in atrial fibrillation]., in Dtsch Med Wochenschr, vol. 135, n. 46, Nov 2010, pp. 2304-8, DOI:10.1055/s-0030-1267516, PMID 21064013.
P. Prandoni, Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study., in Eur J Haematol, vol. 89, n. 4, Oct 2012, pp. 281-7, DOI:10.1111/ejh.12002, PMID 22834998.
AT. Cohen, M. Dobromirski, The use of rivaroxaban for short- and long-term treatment of venous thromboembolism., in Thromb Haemost, vol. 107, n. 6, Jun 2012, pp. 1035-43, DOI:10.1160/TH11-12-0859, PMID 22371186.
B. Brenner, R. Hoffman, Emerging options in the treatment of deep vein thrombosis and pulmonary embolism., in Blood Rev, vol. 25, n. 5, Sep 2011, pp. 215-21, DOI:10.1016/j.blre.2011.04.003, PMID 21605928.
V. Laux, E. Perzborn; S. Heitmeier; G. von Degenfeld; E. Dittrich-Wengenroth; A. Buchmüller; C. Gerdes; F. Misselwitz, Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?, in Thromb Haemost, vol. 102, n. 5, Nov 2009, pp. 892-9, DOI:10.1160/TH09-02-0134, PMID 19888525.
P. Mismetti, S. Laporte, [Rivaroxaban: clinical pharmacology]., in Ann Fr Anesth Reanim, 27 Suppl 3, Dec 2008, pp. S16-21, DOI:10.1016/S0750-7658(08)75142-6, PMID 19185782.

web.archive.org

(EN) Finally a Xarelto Antidote seems to be a reality - Xarelto Lawsuit Information, su Xarelto Lawsuit Information. URL consultato il 1º febbraio 2016 (archiviato dall'url originale il 23 dicembre 2016).
(EN) Andexanet alfa: FXa Inhibitor Antidote - Portola Pharmaceuticals, Inc., su Portola Pharmaceuticals, Inc.. URL consultato il 1º febbraio 2016 (archiviato dall'url originale il 4 marzo 2016).